{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:17:58Z","timestamp":1792534678131,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/ftd.0b013e3181956726","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T11:05:28Z","timestamp":1242903928000},"page":"233-238","source":"Crossref","is-referenced-by-count":69,"title":["Influence of Comedication on Serum Concentrations of Aripiprazole and Dehydroaripiprazole"],"prefix":"10.1097","volume":"31","author":[{"given":"Ragnhild Birkeland","family":"Waade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Rudberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Refsum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","article-title":"Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.","volume":"10","author":"Davies","year":"2004","journal-title":"CNS Drug Rev"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","article-title":"Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole.","volume":"20","author":"Kubo","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-977715","article-title":"Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.","volume":"40","author":"Castberg","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","article-title":"Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.","volume":"22","author":"Kubo","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":"Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.","volume":"63","author":"Hendset","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/jcp.0b013e318056f309","article-title":"Pharmacokinetics of aripiprazole and concomitant carbamazepine.","volume":"27","author":"Citrome","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.ftd.0000249944.42859.bf","article-title":"Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.","volume":"28","author":"Molden","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.ftd.0000189899.23931.76","article-title":"Heterozygous mutation in CYP2C19 significantly increases the concentration\/dose ratio of racemic citalopram and escitalopram (S-citalopram).","volume":"28","author":"Rudberg","year":"2006","journal-title":"Ther Drug Monit"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/humu.10280","article-title":"CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.","volume":"22","author":"Schaeffeler","year":"2003","journal-title":"Hum Mutat"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review.","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00004714-200208000-00014","article-title":"Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.","volume":"22","author":"Spina","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007691-200106000-00007","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.","volume":"23","author":"Spina","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00213-002-1056-8","article-title":"Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.","volume":"162","author":"Ono","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-12-20210129","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.","volume":"29","author":"von Moltke","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R18-12-20210129","first-page":"44","article-title":"Pharmacokinetics of mood stabilizers and new anticonvulsants.","volume":"36","author":"Wang","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270004269870","article-title":"Pharmacokinetics of aripiprazole and concomitant lithium and valproate.","volume":"45","author":"Citrome","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile.","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.403","article-title":"Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes.","volume":"17","author":"Linnet","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction.","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0447.2006.00840.x","article-title":"Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.","volume":"114","author":"Nesvag","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"R24-12-20210129","first-page":"323","article-title":"Lack of pharmacokinetic interaction as an equivalence problem.","volume":"29","author":"Steinijans","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"R25-12-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","article-title":"Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.","volume":"44","author":"Mallikaarjun","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e3181956726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:53:22Z","timestamp":1786038802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200904000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181956726","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}